Table of Content

1. Key Insights

2. Executive Summary of Dilated Cardiomyopathy

3. SWOT Analysis of Dilated Cardiomyopathy

4. Dilated Cardiomyopathy: Market Overview at a Glance

5. Dilated Cardiomyopathy: Disease Background and Overview
5.1. Introduction
5.1.1. Classification Systems and Nomenclature of Cardiomyopathies
5.1.2. Dilated Cardiomyopathy (DCM)
5.1.3. Symptoms of DCM
5.1.4. Causes of DCM
5.1.5. Genetics of DCM
5.1.6. Pathophysiology of DCM

6. Diagnosis
6.1. Diagnosis of DCM
6.1.1. Imaging Techniques
6.1.2. Endomyocardial Biopsy
6.1.3. Non-invasive Arrhythmia Monitoring
6.1.4. Genetic Testing

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Prevalent Population of Dilated Cardiomyopathy in the 7MM
7.3.2. Total Diagnosed Population of Dilated Cardiomyopathy in the 7MM
7.3.3. Familial and non-familial cases of Dilated Cardiomyopathy in the 7MM
7.3.4. Total treated cases of Dilated Cardiomyopathy in the 7MM

8. The United States Epidemiology
8.1. Total Prevalent Population of Dilated Cardiomyopathy in the United States
8.2. Total Diagnosed Population of Dilated Cardiomyopathy in the United States
8.3. Familial and non-familial cases of Dilated Cardiomyopathy in the United States
8.4. Gender-specific cases of Dilated Cardiomyopathy in the United States
8.5. Total treated cases of Dilated Cardiomyopathy in the United States

9. EU-5 Epidemiology
9.1. Germany
9.1.1. Total Prevalent Population of Dilated Cardiomyopathy in Germany
9.1.2. Total Diagnosed Population of Dilated Cardiomyopathy in Germany
9.1.3. Familial and non-familial cases of Dilated Cardiomyopathy in Germany
9.1.4. Gender-specific cases of Dilated Cardiomyopathy in Germany
9.1.5. Total treated cases of Dilated Cardiomyopathy in Germany
9.2. France
9.2.1. Total Prevalent Population of Dilated Cardiomyopathy in France
9.2.2. Total Diagnosed Population of Dilated Cardiomyopathy in France
9.2.3. Familial and non-familial cases of Dilated Cardiomyopathy in France
9.2.4. Gender-specific cases of Dilated Cardiomyopathy in France
9.2.5. Total treated cases of Dilated Cardiomyopathy in France
9.3. Italy
9.3.1. Total Prevalent Population of Dilated Cardiomyopathy in Italy
9.3.2. Total Diagnosed Population of Dilated Cardiomyopathy in Italy
9.3.3. Familial and non-familial cases of Dilated Cardiomyopathy in Italy
9.3.4. Gender-specific cases of Dilated Cardiomyopathy in Italy
9.3.5. Total treated cases of Dilated Cardiomyopathy in Italy
9.4. Spain
9.4.1. Total Prevalent Population of Dilated Cardiomyopathy in Spain
9.4.2. Total Diagnosed Population of Dilated Cardiomyopathy in Spain
9.4.3. Familial and non-familial cases of Dilated Cardiomyopathy in Spain
9.4.4. Gender-specific cases of Dilated Cardiomyopathy in Spain
9.4.5. Total treated cases of Dilated Cardiomyopathy in Spain
9.5. The United Kingdom
9.5.1. Total Prevalent Population of Dilated Cardiomyopathy in the United Kingdom
9.5.2. Total Diagnosed Population of Dilated Cardiomyopathy in the United Kingdom
9.5.3. Familial and non-familial cases of Dilated Cardiomyopathy in the United Kingdom
9.5.4. Gender-specific cases of Dilated Cardiomyopathy in the United Kingdom
9.5.5. Total treated cases of Dilated Cardiomyopathy in the United Kingdom

10. Japan Epidemiology
10.1. Total Prevalent Population of Dilated Cardiomyopathy in Japan
10.2. Total Diagnosed Population of Dilated Cardiomyopathy in Japan
10.3. Familial and non-familial cases of Dilated Cardiomyopathy in Japan
10.4. Gender-specific cases of Dilated Cardiomyopathy in Japan
10.5. Total treated cases of Dilated Cardiomyopathy in Japan

11. Treatment
11.1. Current Treatment Practices of DCM
11.1.1. Pharmacological Therapy
11.1.2. Pacing Therapies for DCM
11.1.3. Surgical Options for DCM

12. Unmet Needs

13. Patient Journey of DCM

14. Marketed Therapy
14.1. Corlanor (ivabradine): Amgen
14.1.1. Product Description
14.1.2. Clinical Studies

15. Emerging Therapies
15.1. PF-07265803/ARRY-371797/ARRY-797: Pfizer
15.1.1. Product Description
15.1.2. Other Development Activities
15.1.3. Clinical Trial Description
15.1.4. Clinical Development
15.1.5. Safety and Efficacy
15.2. Ixmyelocel-T: Vericel
15.2.1. Product Description
15.2.2. Other Development Activities
15.2.3. Clinical Trial Description
15.2.4. Clinical Development
15.2.5. Safety and Efficacy
15.3. BC007: Berlin Cures GmbH
15.3.1. Product Description
15.3.2. Clinical Trial Description
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. Ifetroban: Cumberland Pharmaceuticals
15.4.1. Product Description
15.4.2. Other Development Activities
15.4.3. Clinical Trial Description
15.4.4. Clinical Development
15.5. Danicamtiv/MYK-491: MyoKardia
15.5.1. Product Description
15.5.2. Other Development Activities
15.5.3. Clinical Trial Description
15.5.4. Clinical Development
15.5.5. Safety and Efficacy
15.6. CAP-1002: Capricor Therapeutics
15.6.1. Product Description
15.6.2. Other Development Activities
15.6.3. Clinical Trial Description
15.6.4. Clinical Development
15.6.5. Safety and Efficacy

16. Conjoint Analysis of DCM

17. Dilated Cardiomyopathy: 7 Major Market Analysis
17.1. Key Findings
17.2. Market Size of Dilated Cardiomyopathy in the 7MM
17.3. Market Size of Dilated Cardiomyopathy by therapies in the 7MM
17.4. Market Size of Dilated Cardiomyopathy in the EU-5 countries
17.5. Market Size of Dilated Cardiomyopathy by therapies in the EU-5 countries

18. Market Outlook of DCM in the 7MM

19. The United States: Market Size
19.1. Total Market size of Dilated Cardiomyopathy in the United States
19.2. Market Size of Dilated Cardiomyopathy by therapies in the United States

20. EU-5 countries: Market Size
20.1. Germany Market Size
20.1.1. Total Market size of Dilated Cardiomyopathy in Germany
20.1.2. Market Size of Dilated Cardiomyopathy by therapies in Germany
20.2. France Market Size
20.2.1. Total Market size of Dilated Cardiomyopathy in France
20.2.2. Market Size of Dilated Cardiomyopathy by therapies in France
20.3. Italy Market Size
20.3.1. Total Market size of Dilated Cardiomyopathy in Italy
20.3.2. Market Size of Dilated Cardiomyopathy by therapies in Italy
20.4. Spain Market Size
20.4.1. Total Market size of Dilated Cardiomyopathy in Spain
20.4.2. Market Size of Dilated Cardiomyopathy by therapies in Spain
20.5. The United Kingdom Market Size
20.5.1. Total Market size of Dilated Cardiomyopathy in the United Kingdom
20.5.2. Market Size of Dilated Cardiomyopathy by therapies in the United Kingdom
21. Japan: Market Size
21.1. Total Market size of Dilated Cardiomyopathy in Japan
21.2. Market Size of Dilated Cardiomyopathy by therapies in Japan
22. Access and Reimbursement Overview of Dilated Cardiomyopathy
23. Market Drivers
24. Market Barriers
25. Appendix
25.1. Bibliography
25.2. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight



List of Figures


Figure 1: The European Society of Cardiology (ESC) Classification of Cardiomyopathies
Figure 2: Changes in the Normal Heart after Dilated Cardiomyopathy (DCM)
Figure 3: Symptoms of DCM
Figure 4: Genetic Causes of DCM
Figure 5: The Main Proteins Involved in Cardiomyopathies
Figure 6: Echocardiography and Endomyocardial Biopsy in DCM
Figure 7: Total Prevalent Population of Dilated Cardiomyopathy in the 7MM (2017–2030)
Figure 8: Total Diagnosed Population of Dilated Cardiomyopathy in the 7MM (2017–2030)
Figure 9: Familial and non-familial cases of Dilated Cardiomyopathy in the 7MM (2017–2030)
Figure 10: Total treated cases of Dilated Cardiomyopathy in the 7MM (2017–2030)
Figure 11: Total Prevalent Population of Dilated Cardiomyopathy in the United States (2017–2030)
Figure 12: Total Diagnosed Population of Dilated Cardiomyopathy in the United States (2017–2030)
Figure 13: Familial and non-familial cases of Dilated Cardiomyopathy in the United States (2017–2030)
Figure 14: Gender-specific cases of Dilated Cardiomyopathy in the United States (2017–2030)
Figure 15: Total treated cases of Dilated Cardiomyopathy in the United States (2017–2030)
Figure 16: Total Prevalent Population of Dilated Cardiomyopathy in Germany (2017–2030)
Figure 17: Total Diagnosed Population of Dilated Cardiomyopathy in Germany (2017–2030)
Figure 18: Familial and non-familial cases of Dilated Cardiomyopathy in Germany (2017–2030)
Figure 19: Gender-specific cases of Dilated Cardiomyopathy in Germany (2017–2030)
Figure 20: Total treated cases of Dilated Cardiomyopathy in Germany (2017–2030)
Figure 21: Total Prevalent Population of Dilated Cardiomyopathy in France (2017–2030)
Figure 22: Total Diagnosed Population of Dilated Cardiomyopathy in France (2017–2030)
Figure 23: Familial and non-familial cases of Dilated Cardiomyopathy in France (2017–2030)
Figure 24: Gender-specific cases of Dilated Cardiomyopathy in France (2017–2030)
Figure 25: Total treated cases of Dilated Cardiomyopathy in France (2017–2030)
Figure 26: Total Prevalent Population of Dilated Cardiomyopathy in Italy (2017–2030)
Figure 27: Total Diagnosed Population of Dilated Cardiomyopathy in Italy (2017–2030)
Figure 28: Familial and non-familial cases of Dilated Cardiomyopathy in Italy (2017–2030)
Figure 29: Gender-specific cases of Dilated Cardiomyopathy in Italy (2017–2030)
Figure 30: Total treated cases of Dilated Cardiomyopathy in Italy (2017–2030)
Figure 31: Total Prevalent Population of Dilated Cardiomyopathy in Spain (2017–2030)
Figure 32: Total Diagnosed Population of Dilated Cardiomyopathy in Spain (2017–2030)
Figure 33: Familial and non-familial cases of Dilated Cardiomyopathy in Spain (2017–2030)
Figure 34: Gender-specific cases of Dilated Cardiomyopathy in Spain (2017–2030)
Figure 35: Total treated cases of Dilated Cardiomyopathy in Spain (2017–2030)
Figure 36: Total Prevalent Population of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Figure 37: Total Diagnosed Population of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Figure 38: Familial and non-familial cases of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Figure 39: Gender-specific cases of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Figure 40: Total treated cases of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Figure 41: Total Prevalent Population of Dilated Cardiomyopathy in Japan (2017–2030)
Figure 42: Total Diagnosed Population of Dilated Cardiomyopathy in Japan (2017–2030)
Figure 43: Familial and non-familial cases of Dilated Cardiomyopathy in Japan (2017–2030)
Figure 44: Gender-specific cases of Dilated Cardiomyopathy in Japan (2017–2030)
Figure 45: Total treated cases of Dilated Cardiomyopathy in Japan (2017–2030)
Figure 46: Treatment Goals of DCM
Figure 47: Market size of Dilated Cardiomyopathy in the 7MM, USD Million (2017–2030)
Figure 48: Market size of Dilated Cardiomyopathy by therapies in the 7MM, USD Million (2017–2030)
Figure 49: Market size of Dilated Cardiomyopathy in the EU-5 countries, USD Million (2017–2030)
Figure 50: Market size of Dilated Cardiomyopathy by therapies in the EU-5 countries, USD Million (2017–2030)
Figure 51: Market size of Dilated Cardiomyopathy in the United States, USD Million (2017–2030)
Figure 52: Market size of Dilated Cardiomyopathy by therapies in the United States, USD Million (2017–2030)
Figure 53: Market size of Dilated Cardiomyopathy in Germany, USD Million (2017–2030)
Figure 54: Market size of Dilated Cardiomyopathy by therapies in Germany, USD Million (2017–2030)
Figure 55: Market size of Dilated Cardiomyopathy in France, USD Million (2017–2030)
Figure 56: Market size of Dilated Cardiomyopathy by therapies in France, USD Million (2017–2030)
Figure 57: Market size of Dilated Cardiomyopathy in Italy, USD Million (2017–2030)
Figure 58: Market size of Dilated Cardiomyopathy by therapies in Italy, USD Million (2017–2030)
Figure 59: Market size of Dilated Cardiomyopathy in Spain, USD Million (2017–2030)
Figure 60: Market size of Dilated Cardiomyopathy by therapies in Spain, USD Million (2017–2030)
Figure 61: Market size of Dilated Cardiomyopathy in the United Kingdom, USD Million (2017–2030)
Figure 62: Market size of Dilated Cardiomyopathy by therapies in the United Kingdom, USD Million (2017–2030)
Figure 63: Market size of Dilated Cardiomyopathy in Japan, USD Million (2017–2030)
Figure 64: Market size of Dilated Cardiomyopathy by therapies in Japan, USD Million (2017–2030)

 

List of Tables


Table 1: Summary of DCM Market, Epidemiology, and Key Events (2017–2030)
Table 2: Genes Most Commonly Involved in DCM
Table 3: Total Prevalent Population of Dilated Cardiomyopathy in the 7MM (2017–2030)
Table 4: Total Diagnosed Population of Dilated Cardiomyopathy in the 7MM (2017–2030)
Table 5: Familial and non-familial cases of Dilated Cardiomyopathy in the 7MM (2017–2030)
Table 6: Total treated cases of Dilated Cardiomyopathy in the 7MM (2017–2030)
Table 7: Total Prevalent Population of Dilated Cardiomyopathy in the United States (2017–2030)
Table 8: Total Diagnosed Population of Dilated Cardiomyopathy in the United States (2017–2030)
Table 9: Familial and non-familial cases of Dilated Cardiomyopathy in the United States (2017–2030)
Table 10: Gender-specific cases of Dilated Cardiomyopathy in the United States (2017–2030)
Table 11: Total treated cases of Dilated Cardiomyopathy in the United States (2017–2030)
Table 12: Total Prevalent Population of Dilated Cardiomyopathy in Germany (2017–2030)
Table 13: Total Diagnosed Population of Dilated Cardiomyopathy in Germany (2017–2030)
Table 14: Familial and non-familial cases of Dilated Cardiomyopathy in Germany (2017–2030)
Table 15: Gender-specific cases of Dilated Cardiomyopathy in Germany (2017–2030)
Table 16: Total treated cases of Dilated Cardiomyopathy in Germany (2017–2030)
Table 17: Total Prevalent Population of Dilated Cardiomyopathy in France (2017–2030)
Table 18: Total Diagnosed Population of Dilated Cardiomyopathy in France (2017–2030)
Table 19: Familial and non-familial cases of Dilated Cardiomyopathy in France (2017–2030)
Table 20: Gender-specific cases of Dilated Cardiomyopathy in France (2017–2030)
Table 21: Total treated cases of Dilated Cardiomyopathy in France (2017–2030)
Table 22: Total Prevalent Population of Dilated Cardiomyopathy in Italy (2017–2030)
Table 23: Total Diagnosed Population of Dilated Cardiomyopathy in Italy (2017–2030)
Table 24: Familial and non-familial cases of Dilated Cardiomyopathy in Italy (2017–2030)
Table 25: Gender-specific cases of Dilated Cardiomyopathy in Italy (2017–2030)
Table 26: Total treated cases of Dilated Cardiomyopathy in Italy (2017–2030)
Table 27: Total Prevalent Population of Dilated Cardiomyopathy in Spain (2017–2030)
Table 28: Total Diagnosed Population of Dilated Cardiomyopathy in Spain (2017–2030)
Table 29: Familial and non-familial cases of Dilated Cardiomyopathy in Spain (2017–2030)
Table 30: Gender-specific cases of Dilated Cardiomyopathy in Spain (2017–2030)
Table 31: Total treated cases of Dilated Cardiomyopathy in Spain (2017–2030)
Table 32: Total Prevalent Population of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Table 33: Total Diagnosed Population of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Table 34: Familial and non-familial cases of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Table 35: Gender-specific cases of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Table 36: Total treated cases of Dilated Cardiomyopathy in the United Kingdom (2017–2030)
Table 37: Total Prevalent Population of Dilated Cardiomyopathy in Japan (2017–2030)
Table 38: Total Diagnosed Population of Dilated Cardiomyopathy in Japan (2017–2030)
Table 39: Familial and non-familial cases of Dilated Cardiomyopathy in Japan (2017–2030)
Table 40: Gender-specific cases of Dilated Cardiomyopathy in Japan (2017–2030)
Table 41: Total treated cases of Dilated Cardiomyopathy in Japan (2017–2030)
Table 42: Treatment Options for DCM
Table 43: PF-07265803 (ARRY-371797), Clinical Trial Description, 2020
Table 44: Ixmyelocel-T, Clinical Trial Description, 2020
Table 45: BC007, Clinical Trial Description, 2020
Table 46: Ifetroban, Clinical Trial Description, 2020
Table 47: MYK-491, Clinical Trial Description, 2020
Table 48: CAP-1002, Clinical Trial Description, 2020
Table 49: Market size of Dilated Cardiomyopathy in the 7MM, USD Million (2017–2030)
Table 50: Market size of Dilated Cardiomyopathy by therapies in the 7MM, USD Million (2017–2030)
Table 51: Market Size of Dilated Cardiomyopathy in the EU-5 countries, USD Million (2017–2030)
Table 52: Market size of Dilated Cardiomyopathy by therapies in the EU-5 countries, USD Million (2017–2030)
Table 53: Market size of Dilated Cardiomyopathy in the United States, USD Million (2017–2030)
Table 54: Market size of Dilated Cardiomyopathy by therapies in the United States, USD Million (2017–2030)
Table 55: Market size of Dilated Cardiomyopathy in Germany, USD Million (2017–2030)
Table 56: Market size of Dilated Cardiomyopathy by therapies in Germany, USD Million (2017–2030)
Table 57: Market size of Dilated Cardiomyopathy in France, USD Million (2017–2030)
Table 58: Market size of Dilated Cardiomyopathy by therapies in France, USD Million (2017–2030)
Table 59: Market size of Dilated Cardiomyopathy in Italy, USD Million (2017–2030)
Table 60: Market size of Dilated Cardiomyopathy by therapies in Italy, USD Million (2017–2030)
Table 61: Market size of Dilated Cardiomyopathy in Spain, USD Million (2017–2030)
Table 62: Market size of Dilated Cardiomyopathy by therapies in Spain, USD Million (2017–2030)
Table 63: Market size of Dilated Cardiomyopathy in the United Kingdom, USD Million (2017–2030)
Table 64: Market size of Dilated Cardiomyopathy by therapies in the United Kingdom, USD Million (2017–2030)
Table 65: Market size of Dilated Cardiomyopathy in Japan, USD Million (2017–2030)
Table 66: Market size of Dilated Cardiomyopathy by therapies in Japan, USD Million (2017–2030)